Please use this identifier to cite or link to this item:
|Title:||New initiatives in critical care: distinguishing hype from hope|
|Citation:||Critical Care and Resuscitation, 2016; 18(3):141-147|
|Publisher:||The Australasian Medical Publishing Company|
|John L Moran and Patricia J Solomon|
|Abstract:||Recent viewpoints on critical care have expressed frustration at the slow development of new therapeutic agents and the failure of investigator-initiated trials. Several new directions have been proposed: personalised medicine and the embracing of "omic" technologies, resolving the heterogeneity of treatment effects, and adaptive trial designs. We examine these approaches in the context of analysis of randomised controlled trials (RCTs). The curse of treatment effect heterogeneity is found not only in critical care but also in cancer oncology. We find the uncritical appeal to personalised medicine to be misplaced because such treatments are not identified at the personal level, but at the group or stratified level. The analysis of RCTs has foundered over the problem of accounting for the centre effect and rejecting the random effects approach. Enthusiasm for adaptive trial designs has been articulated at the rhetorical, not the substantive, level.|
|Description:||Critical Care and Resuscitation (CC&R) is the official scientific journal of the College of Intensive Care Medicine (CICM). The paper might also become available in Jan 2017 via https://www.cicm.org.au/Previous-Journal-Editions/CCR-September-2016|
|Rights:||© The Australasian Medical Publishing Company|
|Appears in Collections:||Aurora harvest 7|
Mathematical Sciences publications
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.